Disease patterns and survival rate in children with metastatic soft‐tissue sarcoma: A report from the intergroup rhabdomyosarcoma study (IRS)‐I

@article{Raney1988DiseasePA,
  title={Disease patterns and survival rate in children with metastatic soft‐tissue sarcoma: A report from the intergroup rhabdomyosarcoma study (IRS)‐I},
  author={Richard Beverly Raney and Melvin Tefft and Harold M. Maurer and Abdelsalam H. Ragab and Daniel M. Hays and Edward H. Soule and Mary A. Foulkes and Edmund A. Gehan},
  journal={Cancer},
  year={1988},
  volume={62}
}
The patterns of disease extent, response to treatment, and survival rates were examined in 129 children registered as metastatic (Group IV) soft‐tissue sarcoma patients on the Intergroup Rhabdomyosarcoma Study (IRS)‐I protocol from November 1972 through October 1978. The patients' ages at diagnosis ranged from 3 months to 21 years (median, 10.5 years); 72 were male patients and 57 were female patients (male‐to‐female ratio, 1.3:1). The tumor arose in an extremity in 34 patients, the head and… 
Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.
  • J. Breneman, E. Lyden, W. Crist
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
TLDR
Children with group IV RMS treated on the IRS-IV study had improved OS and FFS if they had two or fewer metastatic sites and embryonal histology, and these patients might not be appropriate candidates for regimens that include experimental agents with substantial toxicities or unproven antitumor activity.
Prognostic Factors and Survival in Late Adolescent and Adult Patients With Small Round Cell Tumors
TLDR
Large-scale, multicenter studies are required for a better eval-uation of the nonpediatric age group with small round cell tumors with nonmetastatic disease, wide and radical resection, and presence of CR to multimodality treatment were associated with a significantly longer PFS and OS by univariate analysis.
CNS Metastases from Bone and Soft Tissue Sarcomas in Children, Adolescents, and Young Adults: Are They Really So Rare?
TLDR
Checking whether primary involvement of brain/spinal cord by bone/soft tissue sarcomas' metastases in children is as rare as described and to present various morphological forms of bone/ soft tissue Sarcoma' CNS metastases found CNS metastase frequencies more frequent than in other reports.
Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.
TLDR
This analysis identified subsets of patients with metastatic rhabdomyosarcoma with different outcomes to current therapy and offers a strategy to define patient candidates for experimental approaches to treatment.
Rhabdomyosarcoma: an overview.
TLDR
The development of intensive multimodality treatment protocols tested in large-scale international trials has resulted in significant improvements in outcome, especially for patients with local or locally extensive disease for whom a 60%-70% disease-free survival can be expected.
Tumor-cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. The Intergroup Rhabdomyosarcoma Study Committee of the Children's Cancer Group and the Pediatric Oncology Group.
  • A. Pappo, W. Crist, D. Shapiro
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1993
TLDR
Tumor-cell ploidy strongly correlates with outcome in children with nonmetastic, unresectable embryonal rhabdomyosarcoma and the two biologically distinct groups identified by this measure would benefit from further refinements in risk-directed therapy.
Prognostic Factors and Treatment Outcomes of Adult Patients With Rhabdomyosarcoma After Multimodality Treatment
TLDR
In addition to staging and histological subtype, the results indicate that concurrent chemoradiotherapy and longer duration of chemotherapy were associated with significantly improved DFS and OS in adult patients with localized RMS.
Adult rhabdomyosarcoma: cross-sectional imaging findings including histopathologic correlation.
TLDR
Although adult rhabdomyosarcomas have certain imaging appearances in common with other soft-tissue sarcomas, features at presentation such as tumor heterogeneity, site, regional lymphadenopathy, and pulmonary metastasis should make the radiologist consider this important diagnosis.
...
...

References

SHOWING 1-10 OF 16 REFERENCES
Soft‐tissue sarcomas in the young. Medical treatment advances in perspective
TLDR
The effectiveness of adjuvant chemotherapy was best seen in patients with stage III disease as a decrease in relapse rate and a lengthening of the time to first relapse, and in these patients it appeared that occult metastatic disease could be eradicated in approximately half of the patients affected.
The intergroup rhabdomyosarcoma study‐I. A final report
TLDR
The authors conclude that for the therapeutic regimens evaluated there was no therapeutic advantage to including radiation in the treatment of Clinical Group I disease, or cyclophosphamide given as a daily low‐dose oral regimen in thetreatment of clinical Group II disease or Adriamycin in the Treatment of Clinical Groups III and IV diseases.
Multidisciplinary treatment of embryonal rhabdomyosarcoma in children
TLDR
Twenty‐nine children under 15 years of age with embryonal rhabdomyosarcoma treated according to a multidisciplinary protocol are alive with no evidence of disease for 4+ to 42+ months, superior to those achieved between 1960–1970 among 108 children treated at Memorial Sloan‐Kettering Cancer Center.
The intergroup rhabdomyosarcoma study. A preliminary report
TLDR
There is no indication as yet that one treatment regimen is superior to the other in the Intergroup Rhabdomyosarcoma Study, and over 85% of patients on either treatment have no evidence of disease and 90% are still alive.
Treatment of rhabdomyosarcoma in children with surgery, radiotherapy and chemotherapy.
From May, 1970 through December, 1972, Children's Cancer Study Group entered 112 patients on an amended treatment program for rhabdomyosarcoma and undifferentiated sarcoma in children. These patients
Extraskeletal Ewing's sarcoma. A preliminary review of 26 cases encountered in the inter group rhabdomyosarcoma study
Twenty‐six of three hundred and fourteen (26/314) patients whose tumors were reviewed by the Pathology Evaluation Committee of the Intergroup Rhabdomyosarcoma Study have histologic subtypes I and II
The improvement in survival associated with combined chemotherapy in childhood rhabdomyosarcoma a historical comparison of 345 patients in the same center
TLDR
The results confirm the overall improvement of survival rates with combined chemotherapy and the greatest benefit from combined chemotherapy was observed in clinical Stage III and IV tumors of the head and neck and of the genitourinary tract.
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
  • J. Miser, T. Kinsella, I. Magrath
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1987
TLDR
At the present time, only seven of the 43 patients who responded to the chemotherapy regimen have relapsed, with a median follow-up of 10 weeks after the response.
A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.
TLDR
Some comparisons are made for five cases of varying degrees of censoring and tying between probabilities from the exact test and those from the proposed test and these suggest the test is appropriate under certain conditions when the sample size is five in each group.
Prognosis in children with metastatic rhabdomyosarcoma.
TLDR
Distant metastases were documented in 83 of 161 children with rhabdomyosarcoma seen between 1953 and 1974 and one child is living with disease at 98 months, and the median durations of life after metastasis were less than 9 months.
...
...